Isolated Humeral Bone Metastasis in Breast Cancer Patient
Languages of publication
The article reports a case of pathological fracture of the left humerus which occurred on the second postoperative day after a right-side modified radical mastectomy in patient primary diagnosed with an early stage of breast cancer. Lack of any clinical symptoms of bone metastasis were observed before surgery. The patient received operative treatment, i.e. resection of diaphyseal lesion and stabilization of the fracture with Rush rods and a plate were performed. Apart from that, bone defect was filled with concrete. In the fifth year of observation the patient feels well, there has been no recurrence of the disease detected. The left upper limb is fully mobile. The role of routine preoperative scintigraphy is discussed.
1 - 11 - 2009
24 - 12 - 2009
- Paterson HG: Management of bone metastases in cancer. American Society of Clinical Oncology. Educational Book 2003; pp. 44-51.
- Coleman RE, Smith P, Rubens RD: Clinical course and prognostic factors following bone recurrence from breast cancer. Cancer 1998; 77: 336-40.
- Semiglazow VE: Histopathological factors for risk of breast cancer bone metastasis. Proceedings of the First International Conference: Cancer-induced bone disease. London 1997; 32.
- Kanis JA, McCloskey EV: Bone turnover and biochemical markers in malignancy. Cancer 1997; 80: 1538-45.
- Mundy GR: Hypercalcemia of malignancy revisited. J Clin Invest 1988; 82: 1-6.
- Yin JJ, Selander K, Chirgwin JM et al.: TGF-ß sygnaling blockade inhibits parathyroid hormone-related protein secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103: 197-206.
- Kakonen SM, Selander KS, Chirgwin JM et al.: Transforming growth factor-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002; 277: 24571-8.
- de la Mata J, Uy HL, Guise TA et al.: Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995; 95: 2846-52.
- Hofbauer LC, Schoppet M: Clinical implications of the steoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490-95.
- Body JJ, Lortholary A, Romieu G et al.: A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97(Suppl 3): 887-92.
- Pederson L, Ruan M, Westendorf JJ et al.: Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. PNAS 2008; 105: 20764-69.
- Clark JC, Dass CR, Choong PF: Current and future treatment of bone metastases. Expert Opinion Emerg Drugs 2008; 13: 609-27.
Publication order reference